Extending the window for acute stroke treatment: Thrombolytics plus CNS protective therapies

Experimental Neurology

Volumn 188, Issue 2, 2004, Pages 195-199

  Wagner, Kenneth R ^a,b   Jauch, Edward C ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CAFFEINE DERIVATIVE; DISUFENTON SODIUM; FIBRINOLYTIC AGENT; N TERT BUTYL ALPHA PHENYLNITRONE; NITRONE DERIVATIVE; STILBAZULENYL NITRONE; TENECTEPLASE; UNCLASSIFIED DRUG;

BEHAVIOR DISORDER; BRAIN HEMORRHAGE; BRAIN INJURY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INDUCED HYPOTHERMIA; NEUROPROTECTION; NOTE; OXIDATIVE STRESS; PLASMA CLEARANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECANALIZATION; RISK ASSESSMENT; SPIN TRAPPING; STROKE; TREATMENT OUTCOME;

ACUTE DISEASE; ANIMALS; BENZENESULFONATES; CENTRAL NERVOUS SYSTEM; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; HUMANS; HYPOTHERMIA, INDUCED; NEUROPROTECTIVE AGENTS; NITROGEN OXIDES; OXIDATIVE STRESS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 3042835547     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.05.006     Document Type: Note

References (56)

1. Adams J.G., Chisholm C.D. The Society for Academic Emergency Medicine position on optimizing care of the stroke patient. Acad. Emerg. Med. 10:2003;805
2. Aronowski J., Strong R., Shirzadi A., Grotta J.C. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke. 34:2003;1246-1251
3. Asahi M., Asahi K., Wang X., Lo E.H. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 20:2000;452-457
4. Becker D.A., Ley J.J., Echegoyen L., Alvarado R. Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants. J. Am. Chem. Soc. 124:2002;4678-4684
5. Berger C., Schabitz W.R., Wolf M., Mueller H., Sommer C., Schwab S. Hypothermia and brain-derived neurotrophic factor reduce glutamate synergistically in acute stroke. Exp. Neurol. 185:2004;305-312
6. Chan P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21:2001;2-14
7. Chapman D.F., Lyden P., Lapchak P.A., Nunez S., Thibodeaux H., Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke. 32:2001;748-752
8. Dietrich W.D., Kuluz J.W. New research in the field of stroke: therapeutic hypothermia after cardiac arrest. Stroke. 34:2003;1051-1053
9. Gibson C.M., Marble S.J. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). Clin. Cardiol. 24:2001;577-584
10. Ginsberg M.D. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis lecture. Stroke. 34:2003;214-223
11. Ginsberg M.D., Sternau L.L., Globus M.Y., Dietrich W.D., Busto R. Therapeutic modulation of brain temperature: relevance to ischemic brain injury. Cerebrovasc. Brain Metab. Rev. 4:1992;189-225
12. Ginsberg M.D., Becker D.A., Busto R., Belayev A., Zhang Y., Khoutorova L., Ley J.J., Zhao W., Belayev L. Stilbazulenyl nitrone, a novel antioxidant, is highly neuroprotective in focal ischemia. Ann. Neurol. 54:2003;330-342
13. Green A.R., Ashwood T., Odergren T., Jackson D.M. Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol. Ther. 100:2003;195-214
14. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V., Bluhmki E., Davis S., Donnan G., Schneider D., Diez-Tejedor E., Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 352:1998;1245-1251
15. Hacke W., Donnan G., Fieschi C., Kaste M., von Kummer R., Broderick J.P., Brott T., Frankel M., Grotta J.C., Haley E.C. Jr., Kwiatkowski T., Levine S.R., Lewandowski C., Lu M., Lyden P., Marler J.R., Patel S., Tilley B.C., Albers G. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 363:2004;768-774
16. Hall N.C., Hua Y., Kothari R.U., De Courten-Myers G.M., Broderick J.P., Brott T., Wagner K.R. α(Phenyl-tert-butylnitrone protects the oxidatively sensitive enzyme creatine kinase in experimental intracerebral hemorrhage. Stroke. 29:1998;273
17. Hall N.C., Packard B.A., Hall C.L., De Courten-Myers G.M., Wagner K.R. Protein oxidation and enzyme susceptibility in white and gray matter with in vitro oxidative stress: relevance to brain injury from intracerebral hemorrhage. Cell. Mol. Biol. 46:2000;673-683
18. Hensley K., Carney J.M., Stewart C.A., Tabatabaie T., Pye Q., Floyd R.A. Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Int. Rev. Neurobiol. 40:1997;299-317
19. Jauch E. Society for Academic Emergency Medicine (SAEM) Neurologic Emergencies Interest Group response to the SAEM board position on optimizing care of the stroke patient. Acad. Emerg. Med. 11:2004;116-118
20. Kleindorfer D., Kissela B., Schneider A., Woo D., Khoury J., Miller R., Alwell K., Gebel J., Szaflarski J., Pancioli A., Jauch E., Moomaw C., Shukla R., Broderick J.P. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 35:2004;e27-e29
21. Kuroda S., Tsuchidate R., Smith M.L., Maples K.R., Siesjo B.K. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 19:1999;778-787
22. Lapchak P.A., Araujo D.M. Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs. 15:2001;819-829
23. Lapchak P.A., Araujo D.M. Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. CNS Drug Rev. 9:2003;253-262
24. Lapchak P.A., Chapman D.F., Zivin J.A. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2, 2, 6, 6- tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke. 32:2001;147-153
25. Lapchak P.A., Araujo D.M., Song D., Wei J., Purdy R., Zivin J.A. Effects of the spin trap agent disodium-[tert-butylimino)methyl]benzene-1, 3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke. 33:2002;1665-1670
26. Lapchak P.A., Araujo D.M., Song D., Wei J., Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1, 3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke. 33:2002;1411-1415
27. Lapchak P.A., Song D., Wei J., Zivin J.A. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp. Neurol. 188:2004;279-285
28. Lees K.R., Sharma A.K., Barer D., Ford G.A., Kostulas V., Cheng Y.F., Odergren T. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke. 32:2001;675-680
29. Lees K.R., Barer D., Ford G.A., Hacke W., Kostulas V., Sharma A.K., Odergren T. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke. 34:2003;482-487
30. Lyden P. Pilot study of tenecteplase (TNK) in acute stroke: preliminary report. Stroke. 34:2003;246
31. Marler J.R., Goldstein L.B. Stroke: tPA and the clinic. Science. 301:2004;1677
32. Marshall J.W., Duffin K.J., Green A.R., Ridley R.M. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 32:2001;190-198
33. Marshall J.W., Cummings R.M., Bowes L.J., Ridley R.M., Green A.R. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke. 34:2003;2228-2233
34. Marshall J.W., Green A.R., Ridley R.M. Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. Brain Res. 972:2003;119-126
35. McCord J.M. Iron, free radicals, and oxidative injury. Semin. Hematol. 35:1998;5-12
36. Mitka M. Tensions remain over tPA for stroke. JAMA. 289:2003;1363-1364
37. NINDS rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J Med. 333:1995;1581-1587
38. Nordt T.K., Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart. 89:2003;1358-1362
39. Pazos A.J., Green E.J., Busto R., McCabe P.M., Baena R.C., Ginsberg M.D., Globus M.Y., Schneiderman N., Dietrich W.D. Effects of combined postischemic hypothermia and delayed N-tert-butyl-alpha-pheylnitrone (PBN) administration on histopathological and behavioral deficits associated with transient global ischemia in rats. Brain Res. 846:1999;186-195
40. Peeling J., Yan H.J., Chen S.G., Campbell M., Del Bigio M.R. Protective effects of free radical inhibitors in intracerebral hemorrhage in rat. Brain Res. 795:1998;63-70
41. Stadtman E.R. Protein oxidation in aging and age-related diseases. Ann. N. Y. Acad. Sci. 928:2001;22-38
42. Stadtman E.R., Berlett B.S. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev. 30:1998;225-243
43. Thomas G.R., Thibodeaux H., Errett C.J., Badillo J.M., Keyt B.A., Refino C.J., Zivin J.A., Bennett W.F. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke. 25:1994;2072-2078
44. Verstraete M. Third-generation thrombolytic drugs. Am. J. Med. 109:2000;52-58
45. Wagner K.R., Broderick J.P. Hemorrhagic stroke: pathophysiological mechanisms and neuroprotective treatments. Lo E.H., Marwah J. Neuroprotection. 2001;471-508 Prominent Press, Scottsdale
46. Wagner K.R., Zuccarello M. Local brain hypothermia for neuroprotection in stroke treatment and aneurysm repair. Neurol. Res. 2004;. (in press)
47. Wagner K.R., Xi G., Hua Y., Kleinholz M., De Courten-Myers G.M., Myers R.E., Broderick J.P., Brott T.G. Lobar intracerebral hemorrhage model in pigs: rapid edema development in perihematomal white matter. Stroke. 27:1996;490-497
48. Wagner K.R., Packard B.A., Hall C.L., Smulian A.G., Linke M.J., De Courten-Myers G.M., Packard L.M., Hall N.C. Protein oxidation and heme oxygenase-1 induction in porcine white matter following intracerebral infusions of whole blood or plasma. Dev. Neurosci. 24:2002;154-160
49. Wagner K.R., Sharp F.R., Ardizzone T.D., Lu A., Clark J.F. Heme and iron metabolism: role in cerebral hemorrhage. J. Cereb. Blood Flow Metab. 23:2003;629-652
50. Wang X., Lo E.H. Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol. Neurobiol. 28:2003;229-244
51. Yealy D.M., Adams J.G. Society for Academic Emergency Medicine (SAEM) Neurologic Emergencies Interest Group response to the SAEM board position on optimizing care of the stroke patient - in reply. Acad. Emerg. Med. 11:2004;118
52. Zausinger S., Scholler K., Plesnila N., Schmid-Elsaesser R. Combination drug therapy and mild hypothermia after transient focal cerebral ischemia in rats. Stroke. 34:2003;2246-2251
53. Zhang R.L., Zhang L., Jiang Q., Zhang Z.G., Goussev A., Chopp M. Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Brain Res. 878:2000;64-71
54. Zheng Z., Lee J.E., Yenari M.A. Stroke: molecular mechanisms and potential targets for treatment. Curr. Mod. Med. 3:2003;361-372
55. Zivin J.A. Thrombolytic stroke therapy: past, present, and future. Neurology. 53:1999;14-19
56. Zivin J.A., Waud D.R. Quantal bioassay and stroke. Stroke. 23:1992;767-773